The use of belatacept in kidney transplantation
Background. Kidney transplantation efficacy is limited by immunosuppression nephrotoxicity, antibody-mediated and chronic rejection. Avoiding immunosuppression nephrotoxicity is a promising strategy to improve long term outcomes. Belatacept, a synthetic immunoglobulin which blocks CD28-B7 pathway of...
Saved in:
| Main Authors: | N. N. Babenko, V. A. Goryainov, M. M. Kaabak, V. V. Nikoda, E. A. Lishova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
2018-09-01
|
| Series: | Трансплантология (Москва) |
| Subjects: | |
| Online Access: | https://www.jtransplantologiya.ru/jour/article/view/394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BELATACEPT IN RENAL TRANSPLANTATION
by: A. I. Sushkov, et al.
Published: (2013-03-01) -
Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients
by: Orhan Efe, et al.
Published: (2024-12-01) -
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review
by: Imran Gani, et al.
Published: (2025-04-01) -
One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients
by: Charlotte Duneton, et al.
Published: (2025-06-01) -
Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen
by: Nathalie Chavarot, et al.
Published: (2025-03-01)